A 62-year-old man presents with stage IV B-cell lymphoma with B symptoms, elevated LDH, and bone marrow involvement. Morphology is intermediate between DLBCL and Burkitt lymphoma. Flow cytometry shows CD20+, CD10+, BCL6+, BCL2+, MUM1–, with Ki-67 of 85%. FISH analysis reveals the pattern shown in the diagram, with the structure marked **A** (MYC + BCL2 rearrangement) confirmed. Which of the following is the MOST appropriate initial management strategy for this patient?

Question

Accepted Answer

B. DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) with intrathecal CNS prophylaxis. ## Why DA-EPOCH-R with intrathecal CNS prophylaxis is right

The structure marked **A** — MYC + BCL2 rearrangement (double-hit lymphoma) — defines a high-grade B-cell lymphoma with VERY POOR PROGNOSIS (2-year OS 30–40% with standard R-CHOP). The concurrent MYC rearrangement drives uncontrolled proliferation while BCL2 rearrangement confers apoptosis resistance, creating an aggressive phenotype. According to WHO 2022/ICC 2022 and NCCN B-NHL 2024 guidelines, standard R-CHOP is INSUFFICIENT for double-hit lymphoma. Intensified chemotherapy (DA-EPOCH-R or R-CODOX-M/IVAC) is mandatory, and intrathecal CNS prophylaxis with methotrexate is mandatory given the 15–30% CNS relapse risk in this subset.

## Why each distractor is wrong

- **Standard R-CHOP without CNS prophylaxis**: R-CHOP alone is inadequate for double-hit lymphoma and results in poor outcomes. CNS prophylaxis is mandatory, not optional, given the high CNS involvement risk (15–30%).
- **R-CHOP followed by observation if CR**: This perpetuates the misconception that R-CHOP is sufficient for double-hit disease. Double-hit lymphoma requires intensified regimens from the outset; observation after R-CHOP is inappropriate.
- **Rituximab monotherapy with surveillance**: Monotherapy is grossly inadequate for an aggressive, proliferative lymphoma with apoptosis resistance. This would result in rapid progression and death.

**High-Yield:** Double-hit lymphoma (MYC + BCL2) = DA-EPOCH-R + mandatory intrathecal CNS prophylaxis; never use R-CHOP alone.

[cite: WHO 2022; ICC 2022; NCCN B-NHL 2024]

Answer

A. Rituximab monotherapy with close surveillance

Answer

C. R-CHOP followed by observation if complete remission is achieved

Answer

D. Standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) without CNS prophylaxis

Explanation

Why DA-EPOCH-R with intrathecal CNS prophylaxis is right

Why each distractor is wrong

Practice similar questions